--- title: "Abbott Laboratories (ABT) news: merger, lawsuit and settlement" url: "https://aibio.space/companies/abbott-laboratories/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ABT merger, lawsuit and settlement news: Abbott agrees to acquire Exact Sciences for $105 per share in cash, about $21 billion." --- ABT Abbott Laboratories NYSE · United States # Abbott Laboratories (ABT) news ABT merger, lawsuit and settlement news Legal · 2026-08-20 ## [Abbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million](https://aibio.space/news/abbott-agrees-settle-gill-case-preterm-formula-nec-claims/) Abbott Laboratories, a defendant in numerous NEC lawsuits, agreed to resolve the Gill case, where a jury awarded $495 million, and claims for about 2,000 other infants. About 1,700 lawsuits remain pending. ## Latest Abbott Laboratories news 1. 2025-11-20 Mergers [Abbott agrees to acquire Exact Sciences for $105 per share in cash, about $21 billion](https://aibio.space/news/abbott-agrees-acquire-exact-sciences-105-share-cash-about-21-billion/) Abbott agreed on November 20, 2025 to buy Exact Sciences for $105 per share in cash, an equity value the companies put at about $21 billion. Abbott's commitment letter provides up to $20 billion of bridge loans, and the companies expect the deal to close in the second quarter of 2026, subject to a shareholder vote and antitrust review. ## Abbott Laboratories at a glance - **Ticker**: ABT - **Listing**: NYSE - **Country**: United States - **Cash, Mar 31, 2026**: $7.29 billion ### Related companies - [Baxter International](https://aibio.space/companies/baxter-international/) NYSE: BAX - [ESTABLISHMENT LABS HOLDINGS INC.](https://aibio.space/companies/establishment-labs/) NASDAQ: ESTA - [Palatin Technologies](https://aibio.space/companies/palatin-technologies/) NASDAQ: PTN - [biote](https://aibio.space/companies/biote/) NASDAQ: BTMD - [Leef Brands](https://aibio.space/companies/leef-brands/) OTC: LEEEF - [CapsoVision](https://aibio.space/companies/capsovision/) NASDAQ: CV - [Immunovant](https://aibio.space/companies/immunovant/) NASDAQ: IMVT - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) NASDAQ: TELO ### Also on NYSE - [QUEST DIAGNOSTICS INC](https://aibio.space/companies/quest-diagnostics/) DGX - [Xtant Medical Holdings](https://aibio.space/companies/xtant-medical/) XTNT - [Elanco Animal Health](https://aibio.space/companies/elanco-animal-health/) ELAN - [Electromed](https://aibio.space/companies/electromed/) ELMD - [Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) RCUS - [REVVITY, INC.](https://aibio.space/companies/revvity/) RVTY ## What Abbott Laboratories does Abbott Laboratories is an Illinois corporation whose principal business is the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. It reports four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. The Established Pharmaceutical Products segment sells branded generic medicines, mainly outside the United States in emerging markets, across gastroenterology, women's health, cardiovascular and metabolic, pain and central nervous system, and respiratory products, including biosimilars. The Diagnostic Products segment offers laboratory, molecular and point-of-care systems and tests for areas such as cancer, cardiac and metabolic disorders, infectious diseases and drugs of abuse, including the Alinity family of instruments. The Nutritional Products segment sells infant formula such as Similac and adult and pediatric nutrition products such as Ensure, Glucerna and PediaSure. On November 19, 2025, Abbott agreed to acquire Exact Sciences Corporation, which is expected to enable Abbott to enter the cancer diagnostics market. The deal is subject to customary closing conditions, including approval by Exact Sciences shareholders and required regulatory clearances. | Product or program | What it is | Stage | |---|---|---| | Creon | Treats pancreatic exocrine insufficiency from cystic fibrosis and chronic pancreatitis | | | Alinity family of instruments | Core laboratory and molecular diagnostic systems | | | Similac infant formula | Pediatric infant and follow-on formula products | | | Ensure | Adult nutritional products | | Summarised from the company's [10-K filed Feb 20, 2026](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm). ## Abbott Laboratories annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$44.33 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | [$41.95 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | | Research and development | [$2.94 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | [$2.84 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | | Net income (loss) | [$6.52 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | [$13.40 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | | Cash from operations | [$9.57 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | [$8.56 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | | Cash and equivalents | [$8.52 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/) | [$7.62 billion](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | | Short-term investments | [$417.0 million](https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/) | [$351.0 million](https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $6.80 billion, plus short-term investments of $492.0 million, $7.29 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Abbott Laboratories Is Abbott Laboratories involved in a merger or acquisition? Our latest story on this, dated Nov 20, 2025: "Abbott agrees to acquire Exact Sciences for $105 per share in cash, about $21 billion". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/abbott-agrees-acquire-exact-sciences-105-share-cash-about-21-billion/). Is Abbott Laboratories involved in a lawsuit? Our latest story on this, dated Aug 20, 2026: "Abbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/abbott-agrees-settle-gill-case-preterm-formula-nec-claims/). Has Abbott Laboratories settled a lawsuit? Our latest story on this, dated Aug 20, 2026: "Abbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/abbott-agrees-settle-gill-case-preterm-formula-nec-claims/). What is the ticker symbol of Abbott Laboratories? Abbott Laboratories trades under the ticker ABT on NYSE. Where is Abbott Laboratories listed? Abbott Laboratories is listed on NYSE. What is the SEC CIK of Abbott Laboratories? The SEC Central Index Key (CIK) for Abbott Laboratories is 1800. Its filings are on SEC EDGAR. Which country or territory is Abbott Laboratories listed under? Our directory records Abbott Laboratories under United States. What does Abbott Laboratories do? Our directory classifies Abbott Laboratories as: Diversified pharmaceuticals/medtech. This is a directory classification, not a description of the pipeline. What is the ISIN of Abbott Laboratories? The ISIN recorded for Abbott Laboratories is US0028241000. Does aibio.space cover Abbott Laboratories? aibio.space lists Abbott Laboratories among 2,820 public biotech companies and publishes its news here as stories appear. Where is Abbott Laboratories incorporated? SEC records list its state or country of incorporation as IL. What does Abbott Laboratories develop? Abbott Laboratories is an Illinois corporation whose principal business is the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. It reports four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. What is Creon from Abbott Laboratories? Creon: Treats pancreatic exocrine insufficiency from cystic fibrosis and chronic pancreatitis What is Alinity family of instruments from Abbott Laboratories? Alinity family of instruments: Core laboratory and molecular diagnostic systems What was Abbott Laboratories's revenue last year? $44.33 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Abbott Laboratories Members talk about Abbott Laboratories (ABT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Abbott Laboratories, newest first. Each line links the filing it comes from. 1. 2026-04-17 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1800/000110465926044892/tm2611915d1_ex99-1.htm) 2. 2026-03-23 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1800/000110465926033079/tm268709d2_ex99-1.htm) 3. 2026-02-25 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1800/000110465926019401/tm264905-5_424b5.htm) 4. 2025-11-20 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/tm2531676d2_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:ABT on TradingView](https://www.tradingview.com/symbols/NYSE-ABT/). ## SEC filings and registration - **SEC name**: Abbott Laboratories - **CIK**: 1800 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ABT (NYSE) - **State or country of incorporation**: IL - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500 - **Phone**: 2246676100 ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1800/000110465926117587/tm2627971d1_8k.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1800/000162828026066601/abt-20261021.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1800/000110465926099247/tm2623675d1_8k.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1800/000162828026050134/abt-20260630.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-20260716.htm) filed 2026-07-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1800/000162828026028357/abt-20260331.htm) filed 2026-04-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1800/000110465926049434/tm2612318d1_8k.htm) filed 2026-04-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1800/000110465926044892/tm2611915d1_8k.htm) filed 2026-04-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Abbott Laboratories is a public biotech or pharmaceutical company listed on NYSE under the ticker ABT, recorded under United States. The directory classifies it as Diversified pharmaceuticals/medtech. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Abbott Laboratories - **Ticker**: ABT - **Listing**: NYSE - **Country or territory**: United States - **Business scope**: Diversified pharmaceuticals/medtech - **ISIN**: US0028241000 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://abbott.mediaroom.com/2026-10-21-Abbott-Reports-Third-Quarter-2026-Results-and-Reaffirms-Full-Year-EPS-Guidance) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/abbott-laboratories/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Abbott Laboratories (ABT) news: merger, lawsuit and settlement", 2026-10-31, https://aibio.space/companies/abbott-laboratories/